Back to News
investment

Should You Buy Hims Stock Today?

newsfeedback@fool.com (Parkev Tatevosian, CFA)
Loading...
2 min read
0 likes
⚡ Quantum Brief
Hims & Hers stock surged 30% in March 2026 after announcing a partnership with Novo Nordisk to distribute its weight-loss drugs, capitalizing on the booming GLP-1 medication market. The stock remains highly volatile, with sharp fluctuations including a 10% drop on March 12 as investors took profits following the rally triggered by the Novo Nordisk deal. An unnamed asset manager exited its position entirely on March 10, signaling potential skepticism about long-term growth despite the short-term hype around the weight-loss drug collaboration. Analysts note the company’s reliance on consumer demand for telehealth services and prescription medications, which could face regulatory or competitive risks in the evolving healthcare sector. As of March 30, 2026, shares traded at $19.16, down 3.45%, reflecting ongoing uncertainty about whether the stock’s valuation justifies its recent volatility and growth prospects.
AI Audio Summary
0:00 / 0:00
Click to play
Gemini_Generated_Image_h5l2xxh5l2xxh5l2 (1).png
Quantum News · Media Library

By Parkev Tatevosian, CFA – Apr 2, 2026 at 9:43PM ESTHims & Hers (HIMS 3.53%) has been one of the most volatile stocks in the markets in recent months. *Stock prices used were the afternoon prices of March 30, 2026. The video was published on April 2, 2026. Read NextMar 25, 2026 •By Motley Fool StaffSurging Oil Prices Spark Market JittersMar 17, 2026 •By Brett SchaferTop 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise MoveMar 12, 2026 •By Jeff SantoroStock Market Today, March 12: Hims and Hers Health Drops After Rally Sparks Profit TakingMar 10, 2026 •By Dave KovaleskiAsset Manager Exits Shares of Hims & Hers HealthMar 9, 2026 •By Josh Kohn-LindquistStock Market Today, March 9: Hims & Hers Health Soars on Novo Nordisk Weight-Loss Drug DealMar 9, 2026 •By Geoffrey SeilerHims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?About the AuthorA Fool since 2019, and a graduate of Cal State LA with a B.S. in Finance and M.A. in Economics. Parkev is an adjunct professor of Finance and enjoys reading about financial and economic history. You'll often find him writing about stocks in the consumer goods and technology sectors.TMFParkevX@TMFParkevStocks MentionedHims & Hers HealthNYSE: HIMS$19.16(-3.45%)-$0.69*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Read Original

Source Information

Source: The Motley Fool

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.